Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
On Thursday, Ascendiant Capital analysts increased the price target for Myomo Inc . (NYSE: NYSE:MYO) stock to $11.50 from the previous target of $11.00, representing a significant upside from the current price of $2.88. The firm continues to maintain a Buy rating on the stock. According to InvestingPro data, the company maintains a GOOD financial health score, with a robust gross profit margin of 71%.
The analysts highlighted the current valuation of Myomo stock as attractive, citing a net present value analysis. This analysis suggests significant potential upside from the current share price, which is trading near its 52-week low. The company’s strong financial position is evidenced by its healthy current ratio of 2.66 and more cash than debt on its balance sheet.
Ascendiant Capital’s evaluation considers the risks associated with the company while also acknowledging its high growth prospects and substantial upside opportunities. The revised price target reflects these considerations.
Myomo Inc. remains under the Buy category, with the adjusted price target indicating confidence in the company’s future performance.
In other recent news, Myomo Inc reported a notable increase in its first-quarter 2025 revenue, which grew by 162% year-over-year to $9.8 million, surpassing analyst expectations of $9.3 million. The company’s earnings per share met forecasts at -$0.08. Despite this financial performance, Myomo recorded a net loss of $3.5 million. The company also reported an improvement in gross margin, rising to 67.2% from 61.2% in the previous year. Looking ahead, Myomo has projected revenue between $9 million and $9.5 million for the second quarter of 2025, indicating an expected year-over-year growth of 20-26%. The company aims to achieve positive operating cash flow by the fourth quarter of 2025. Additionally, Myomo has been working on expanding its orthotics and prosthetics distribution channel and has introduced product upgrades, including the MyoPro 2X. The company is also focusing on international growth, particularly in Germany, which contributed $1.3 million to quarterly revenue.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.